how was semaglutide discovered 30 years of obesity research and over 100 years of medical breakthroughs. Learn more about and the story behind the discovery here: https://lnkd.in/e_as9aKV | Novo Nordisk History of glucagon-like peptide-1 receptor

1000mg Av

#BMS #Cobenfy #schizophrenia #psychiatry Biotech Executive, Thought Leader & Creator | Diagnostics Executive | Microfluidics & Immunoassay Innovation | FDA Strategy Led EUA 230055, EUA 240006 & 510(k) K240728 | Oncology, AIBiology & IVD Commercialization Market Watch | Bristol Myers Squibbs Cobenfy Faces Uptake Challenges Amid Strong Q3 Earnings Bristol Myers Squibb ($BMY) reported $12.2B in Q3 revenue, surpassing analyst expectations yet investor attention centered on Cobenfy, the first new schizophrenia drug in 35 years, which posted $43M in sales, slightly below forecasts

Minimum side effect disruption

For non-diabetic users the question is whether both are needed: tirzepatide is far stronger for weight loss at 5 mg and above, while metformin is cheaper, oral, and more modest

These two targeted iFIT programs offer guided paths to protect your muscle and support your long-term success

If your weight plateaus for several months while on a stable dose, it might be time to revisit your strategy with your provider